Mpox Vaccine
Two vaccines are available to prevent or lessen the severity of mpox for exposed individuals in the United States: JYNNEOS (Imvamune or Imvanex) and ACAM2000. JYNNEOS is the preferred vaccine for the current outbreak of mpox. Mpox can be prevented if the vaccine is given up to four days after exposure. Vaccine given after four and up to fourteen days after exposure could reduce the severity of the illness but might not prevent the disease.
Download What is JYNNEOS Vaccine for Mpox and Who is Eligible?
Visit Locations for a list of county health departments in Alabama.
Most Asked Questions
The mpox pre-exposure vaccine should be offered to people with the highest potential for exposure to mpox such as:
- Gay, bisexual, and other men who have sex with men, transgender or nonbinary people who in the past 6 months have had:
- A new diagnosis of one or more nationally reportable sexually transmitted diseases (i.e., acute HIV, chancroid, chlamydia, gonorrhea, or syphilis)
- More than one sex partner
- People who have had any of the following in the past 6 months:
- Sex at a commercial sex venue
- Sex in association with a large public event in a geographic area where mpox transmission is occurring
- Sexual partners of people with the above risks
- People who anticipate experiencing the above risks
- People who are deemed at higher risk for mpox infections by the managing clinician or other factors
Download What is JYNNEOS Vaccine for Mpox and Who is Eligible?
Visit Locations for a list of county health departments in Alabama.
Previous vaccination against smallpox may provide limited protection since both diseases are from the same family of viruses. People vaccinated against smallpox, in the past, will have some protection against mpox. People below the 40-50 age group are unlikely to have been inoculated against smallpox since vaccination ended in the world by 1980. Some people received the smallpox vaccine after 9/11 if they were first responders or medical personnel.
Persons who were previously vaccinated against smallpox, but have a reason to be vaccinated in this outbreak, due to mpox exposure or higher risk factors, should receive two doses of Jynneos. Persons administering Jynneos do not need to take the vaccine unless they have higher risk factors.
Resources
- Mpox Vaccine (CDC)
- Vaccine Effectiveness (CDC)
- CDC MMWR - Use of JYNNEOS (Smallpox and Mpox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses
- JYNNEOS Mpox Vaccine Distribution by Jurisdiction
- JYNNEOS Vaccine (FDA)
- Immunize.org (IAC) - Mpox
- FACT SHEET: Biden Administration Announces Key Actions and Implementation Plan to Increase Vaccine Supply
- Interim Clinical Considerations for Use of JYNNEOS and ACAM2000 Vaccines during the 2022 U.S. Mpox Outbreak
- Mpox Update: FDA Authorizes Emergency Use of JYNNEOS Vaccine to Increase Vaccine Supply
- HHS Secretary Becerra issues 564 determination, paving way for emergency use authorization of mpox vaccines
Page last updated: December 1, 2022